2026-10-19T02:05:09Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/125492026-10-18T21:13:26Zopenairedrivercom_ebyu_10000col_ebyu_10001

Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world studyCil, IbrahimKucukarda, AhmetAtcı, Muhammed MustafaSecmeler, SabanPaksoy, NailFerhatoglu, FerhatAk, NaziyeAyhan, MuratTataroglu Ozyukseler, DenizOnder, Arif HakanAvci, OkanOyman, AbdilkerimOkten, Ilker NihatGulturk, IlkayAkagunduz, BaranBasoglu, TugbaCakir, EmreHacibekiroglu, IlhanOzcelik, MelikeAydiner, AdnanHER2 positivemetastatic breast cancerolder patientsreal-worldAdo-Trastuzumab EmtansineAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBreast NeoplasmsDrug-Related Side Effects and Adverse ReactionsFemaleHumansProgression-Free SurvivalProportional Hazards ModelsReceptor, ErbB-2Retrospective Studiesalanine aminotransferaseaspartate aminotransferaseepidermal growth factor receptor 2estrogen receptorprogesterone receptortrastuzumab emtansineERBB2 protein, humanmonoclonal antibodyadvanced breast canceralanine aminotransferase blood levelanemiaArticleaspartate aminotransferase blood levelbrain metastasisIntroduction: Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, clinical trials underrepresent patients ⩾65 years of age, leading to a lack of information in this population. We analyzed the real-world outcomes of older women who were treated with T-DM1 therapy. Methods: We performed a multicenter, observational, retrospective analysis of patients aged ⩾65 years treated with T-DM1. A total of 93 patients from 10 cancer centers were involved in the study. Our goal was to determine the survival, response rates, and toxicity profile in T-DM1–treated patients, as well as the factors that influence survival. Results: Median follow-up was 12.2 months. Objective response rate was 29%. Median progression-free survival (PFS) and overall survival (OS) were 8.47 and 15.0 months, respectively. In multivariate analysis, Eastern Cooperative Oncology Group Performance Score 2 was found to be an independent prognostic factor for worse PFS (hazard ratio [HR] 1.81, p = 0.032) and OS (HR 2.33, p = 0.006). Any adverse event (AE) was seen in 92.5% of patients; grade 3 or 4 AEs were seen in 30.1%. Dose reduction or treatment discontinuation rates were 11.8% and 6.5%, respectively. Conclusion: The efficacy of T-DM1 was acceptable and it was generally well-tolerated among older patients with advanced HER2-positive breast cancer. © Fondazione IRCCS Istituto Nazionale dei Tumori 2021.SAGE Publications Ltd2022Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12549https://doi.org/10.1177/030089162110377390300-8916enTumoriinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12549